Serum interleukin-27 expression in patients with myasthenia gravis

Ha Neul Jeong; Jung Hwan Lee; Bum Chun Suh; Young Chul Choi

doi:10.1016/j.jneuroim.2015.09.010

Serum interleukin-27 expression in patients with myasthenia gravis

Ha Neul Jeong, Jung Hwan Lee, Bum Chun Suh, Young Chul Choi

Department of Neurology

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

Myasthenia gravis (MG)¹1MG (myasthenia gravis). is an autoimmune disease directed at the neuromuscular junction, and cytokines are thought to contribute to its immunopathogenesis. Interleukin-27 (IL-27)²2IL-27 (interleukin-27). plays a complex and pleiotropic role in immune responses associated with T helper cells. To assess the role of IL-27 in MG, we determined serum IL-27 levels in MG patients (n = 32) compared to healthy controls (n = 50). The median serum IL-27 level was significantly higher in MG patients (35.947 pg/mL) than in controls (19.885 pg/mL). Furthermore, serum IL-27 was significantly higher in early onset MG. This study suggests the possibility that IL-27 might contribute to MG pathogenesis or immunoregulation.

Original language	English
Pages (from-to)	120-122
Number of pages	3
Journal	Journal of Neuroimmunology
Volume	288
DOIs	https://doi.org/10.1016/j.jneuroim.2015.09.010
Publication status	Published - 2015 Nov 15

Bibliographical note

Publisher Copyright:
© 2015 Elsevier B.V..

All Science Journal Classification (ASJC) codes

Immunology and Allergy
Immunology
Neurology
Clinical Neurology

Access to Document

10.1016/j.jneuroim.2015.09.010

Cite this

@article{da1f1f05ca6f4991a67a72fc5bac3283,

title = "Serum interleukin-27 expression in patients with myasthenia gravis",

abstract = "Myasthenia gravis (MG)11MG (myasthenia gravis). is an autoimmune disease directed at the neuromuscular junction, and cytokines are thought to contribute to its immunopathogenesis. Interleukin-27 (IL-27)22IL-27 (interleukin-27). plays a complex and pleiotropic role in immune responses associated with T helper cells. To assess the role of IL-27 in MG, we determined serum IL-27 levels in MG patients (n = 32) compared to healthy controls (n = 50). The median serum IL-27 level was significantly higher in MG patients (35.947 pg/mL) than in controls (19.885 pg/mL). Furthermore, serum IL-27 was significantly higher in early onset MG. This study suggests the possibility that IL-27 might contribute to MG pathogenesis or immunoregulation.",

author = "Jeong, {Ha Neul} and Lee, {Jung Hwan} and Suh, {Bum Chun} and Choi, {Young Chul}",

note = "Publisher Copyright: {\textcopyright} 2015 Elsevier B.V..",

year = "2015",

month = nov,

day = "15",

doi = "10.1016/j.jneuroim.2015.09.010",

language = "English",

volume = "288",

pages = "120--122",

journal = "Advances in Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier",

}

TY - JOUR

T1 - Serum interleukin-27 expression in patients with myasthenia gravis

AU - Jeong, Ha Neul

AU - Lee, Jung Hwan

AU - Suh, Bum Chun

AU - Choi, Young Chul

PY - 2015/11/15

Y1 - 2015/11/15

N2 - Myasthenia gravis (MG)11MG (myasthenia gravis). is an autoimmune disease directed at the neuromuscular junction, and cytokines are thought to contribute to its immunopathogenesis. Interleukin-27 (IL-27)22IL-27 (interleukin-27). plays a complex and pleiotropic role in immune responses associated with T helper cells. To assess the role of IL-27 in MG, we determined serum IL-27 levels in MG patients (n = 32) compared to healthy controls (n = 50). The median serum IL-27 level was significantly higher in MG patients (35.947 pg/mL) than in controls (19.885 pg/mL). Furthermore, serum IL-27 was significantly higher in early onset MG. This study suggests the possibility that IL-27 might contribute to MG pathogenesis or immunoregulation.

AB - Myasthenia gravis (MG)11MG (myasthenia gravis). is an autoimmune disease directed at the neuromuscular junction, and cytokines are thought to contribute to its immunopathogenesis. Interleukin-27 (IL-27)22IL-27 (interleukin-27). plays a complex and pleiotropic role in immune responses associated with T helper cells. To assess the role of IL-27 in MG, we determined serum IL-27 levels in MG patients (n = 32) compared to healthy controls (n = 50). The median serum IL-27 level was significantly higher in MG patients (35.947 pg/mL) than in controls (19.885 pg/mL). Furthermore, serum IL-27 was significantly higher in early onset MG. This study suggests the possibility that IL-27 might contribute to MG pathogenesis or immunoregulation.

UR - http://www.scopus.com/inward/record.url?scp=84945545370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945545370&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2015.09.010

DO - 10.1016/j.jneuroim.2015.09.010

M3 - Article

C2 - 26531704

AN - SCOPUS:84945545370

SN - 0165-5728

VL - 288

SP - 120

EP - 122

JO - Advances in Neuroimmunology

JF - Advances in Neuroimmunology

ER -

Serum interleukin-27 expression in patients with myasthenia gravis

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this